The Venture Capital magazine examines the price level of buyout transactions this spring, with a special focus on medical technology. Experts classify the industry as very promising, but rate the prices as often not justified. Hubertus Leonhardt, Managing Partner at SHS Gesellschaft für Beteiligungsmanagement mbH, points out that buyout transactions are often about more than […]

WirtschaftsWoche reports on the third investment of SHS from its current fund SHS V. Betterguards Technology GmbH, founded in 2014 and headquartered in Berlin with a production facility in Brandenburg, develops and produces intelligent components (so-called adaptors) that can be integrated into sports shoes, bandages or work protection shoes, for example. Equipped with this unique […]

Third investment from fifth SHS fund – development of a diversified portfolio of medical technology and life science companies TTübingen-based medical technology investor SHS Gesellschaft für Beteiligungsmanagement mbH has invested a mid single-digit million amount from its fifth fund in Betterguards Technology GmbH. The technology developed and produced by the Berlin-Brandenburg-based company is primarily aimed […]

c-LEcta, an innovative SHS portfolio company in the field of white biotechnology, reports in the Süddeutsche Zeitung on how its enzymes are used to produce new sweeteners based on the stevia plant. The sweeteners developed jointly with industrial partners already have FDA approval in the USA, where sugar substitutes are used in beverages and food. […]

The private equity news portal Unquote evaluates the effects of the new German Scheduling and Supply Act and refers to the opportunities and risks of the global medical technology market. Despite tougher regulations, experts do not expect an economic slowdown for the medical technology, life science and biotechnology industries. Dr. Andre Zimmermann, Partner at SHS […]

The concept with which the Graz-based company Tyromotion made it from university to world market leader is taken up in “die wirtschaft”. The SHS portfolio company from the SHS IV fund develops robotic and computer-supported therapy devices that support patients in rehabilitation after a stroke, multiple sclerosis or spinal cord injury. Tyromotion uses a playful […]

The SHS V fund managed by Tübingen-based SHS Gesellschaft für Beteiligungsmanagement has acquired a joint stake in Swiss evitria AG together with AFINUM. The life science company supplies large pharmaceutical and biotech companies with customized antibodies for research purposes. For SHS, it is the first investment from its SHS V fund, which had its first […]

With a long tradition and as one of the largest hospitals in Germany, Olgahospital (“Olgäle”) focuses on treating sick children and young people. “Olgäle-Stiftung für das kranke Kind e. V.” (Olgäle foundation for sick children) was founded 20 years ago under the patronage of Carl, Duke of Württemberg. The foundation strives to ensure permanent aid […]

The Zollernalb-Tübingen Regional Group of Mukoviszidose e.V. is a self-help group consisting of 35 parents whose children suffer from cystic fibrosis. This incurable metabolic disease leads to a significant reduction in life expectancy. The cause of the disease is a gene mutation. Every 20th person in Germany carries the defective gene. Only if both parents […]

SHS Gesellschaft fuer Beteiligungsmanagement, MBG Baden-Württemberg and VC Fonds BW announced that Emerging Implant Technologies GmbH (EIT), a manufacturer of 3D-printed titanium interbody implants for spinal fusion surgery, has been acquired by Johnson & Johnson Medical GmbH. SHS became EIT’s lead investor in September 2016. Since then the Tuebingen based medtech specialist has subsequently supported […]

Digitization in the healthcare industry is progressing only very slowly due to the high density of regulation and complex development procedures. SHS will now invest its fifth fund (planned volume: EUR 150 million) in digital health companies for the first time. SHS Managing Partner Hubertus Leonhardt outlines the particular difficulties involved in investing in medical […]

The financing of new products in the health care industry is often difficult in Germany, as there is a lack of capital. The SHS Beteiligungsgesellschaft is now providing new capital, at least for some of the inventors: In the so-called First Closing, SHS has received commitments for more than 90 million euros from investors in […]